Should I buy or sell Altimmune stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Altimmune in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ALT shares. View ALT analyst ratings or view top-rated stocks .

What is Altimmune's stock price target for 2024?

3 Wall Street research analysts have issued 1-year target prices for Altimmune's shares. Their ALT share price targets range from $12.00 to $20.00. On average, they predict the company's share price to reach $15.00 in the next twelve months. This suggests a possible upside of 117.1% from the stock's current price. View analysts price targets for ALT or view top-rated stocks among Wall Street analysts .

How have ALT shares performed in 2024?

Altimmune's stock was trading at $11.25 at the start of the year. Since then, ALT shares have decreased by 38.6% and is now trading at $6.91. View the best growth stocks for 2024 here .

When is Altimmune's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ALT earnings forecast .

How were Altimmune's earnings last quarter?

Altimmune, Inc. (NASDAQ:ALT) announced its quarterly earnings data on Monday, November, 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by $0.45. The business earned $0.16 million during the quarter, compared to analyst estimates of $0.11 million. Altimmune had a negative trailing twelve-month return on equity of 44.77% and a negative net margin of 20,780.75%. During the same period in the previous year, the firm posted ($0.54) earnings per share.

When did Altimmune's stock split?

Altimmune's stock reverse split on the morning of Friday, September 14th 2018. The 1-30 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Altimmune own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Altimmune investors own include Vaxart (VXRT) , Pfizer (PFE) , Verizon Communications (VZ) , Amarin (AMRN) , Advanced Micro Devices (AMD) , Albireo Pharma (ALBO) , Alliance Data Systems (ADS) , AcelRx Pharmaceuticals (ACRX) , Albertsons Companies (ACI) and Achieve Life Sciences (ACHV) .

Who are Altimmune's major shareholders?

Altimmune's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include IMC Chicago LLC (0.00%) and EWG Elevate Inc. (0.01%). Insiders that own company stock include David Drutz, Diane Jorkasky, M Scot Roberts, Matthew Scott Harris , Vipin K Garg and Wayne Pisano. View institutional ownership trends .

How do I buy shares of Altimmune?

Shares of ALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ALT

Altimmune (ALT) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free ALT Stock Alerts

$6.91

+0.02 (+0.29%)

(As of 04/19/2024 ET)

Compare

Today's Range: $6.64
▼
$7.01
50-Day Range: $6.89
▼
$13.81
52-Week Range: $2.09
▼
$14.84

Volume: 3.59 million shs
Average Volume: 5.50 million shs
Market Capitalization: $489.85 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.00

Get Altimmune alerts:

Altimmune MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 117.1% Upside
$15.00 Price Target
Short Interest: Bearish
25.01% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.15
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.52) to ($1.95) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.12 out of 5 stars

Medical Sector

761st out of 911 stocks

Pharmaceutical Preparations Industry

337th out of 411 stocks

3.3

Analyst's Opinion

Consensus Rating
Altimmune has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Altimmune has only been the subject of 3 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
25.01% of the outstanding shares of Altimmune have been sold short.
Short Interest Ratio / Days to Cover
Altimmune has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Altimmune has recently increased by 41.73%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Altimmune does not currently pay a dividend.
Dividend Growth
Altimmune does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ALT.

1.7

News and Social Media Coverage

News Sentiment
Altimmune has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Altimmune this week, compared to 4 articles on an average week.
Search Interest
Only 82 people have searched for ALT on MarketBeat in the last 30 days. This is a decrease of -19% compared to the previous 30 days.
MarketBeat Follows
31 people have added Altimmune to their MarketBeat watchlist in the last 30 days. This is an increase of 94% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Altimmune insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.10% of the stock of Altimmune is held by insiders.
Percentage Held by Institutions
78.05% of the stock of Altimmune is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Altimmune are expected to decrease in the coming year, from ($1.52) to ($1.95) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Altimmune is -4.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Altimmune is -4.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Altimmune has a P/B Ratio of 2.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Altimmune Stock (NASDAQ:ALT)

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

ALT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ALT Stock News Headlines

April 9, 2024 | marketbeat.com

Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?

Altimmune Inc. NASDAQ: ALT is a clinical-stage biotechnology company specializing in treating liver disease and obesity. Their lead drug, Pemvidutide, has garnered much attention as a GLP-1/glucagon dual agonist similar to the weight-loss treatments Mounjaro and Zepbound by Eli Lilly and Co. NYSE: LLY.

April 9, 2024 | marketbeat.com

Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?

Altimmune has a GLP-1 candidate in Phase 2 trials, but the company continues to burn cash and may need a big pharma partner to get its drug to market

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

March 28, 2024 | marketbeat.com

7 Stocks That Will Drive the Weight Loss Drugs Market (ALT)

The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis.

April 19, 2024 | finance.yahoo.com

Global COVID-19 Testing Strategic Analysis Report 2024: Market to Reach $5.8 Billion by 2030 from $19.9 Billion in 2023

April 18, 2024 | finance.yahoo.com

Altimmune, Inc. (ALT)

April 12, 2024 | seekingalpha.com

Buy Altimmune's Potential Market Disruption With Pemvidutide

April 11, 2024 | investorplace.com

3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

April 9, 2024 | fool.com

Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.

April 1, 2024 | investorplace.com

The 3 Best Biotech Stocks to Buy in April 2024

April 1, 2024 | markets.businessinsider.com

Altimmune’s Pemvidutide Shows Promise for Obesity Treatment, Justifying Buy Rating

March 31, 2024 | seekingalpha.com

Eli Lilly: Three Threats To Its Huge Rally

March 29, 2024 | msn.com

A new Ozempic rival helps patients lose fat, but keep their muscle — the holy grail for a weight-loss drug

March 28, 2024 | finance.yahoo.com

Altimmune, Inc. (NASDAQ:ALT) Q4 2023 Earnings Call Transcript

March 28, 2024 | msn.com

Altimmune says weight loss drug minimized muscle loss in trial results, which may set it apart

March 28, 2024 | ca.finance.yahoo.com

Q4 2023 Altimmune Inc Earnings Call

March 27, 2024 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Altimmune (ALT)

March 27, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Altimmune as Pemvidutide Shows Promising Weight Loss and Lean Mass Preservation

March 27, 2024 | seekingalpha.com

Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place

March 27, 2024 | cnbc.com

Altimmune says weight loss drug minimized muscle loss in trial results that may set it apart

March 27, 2024 | msn.com

What To Know About Permvidutide—Altimmune Says Weight Loss Drug Minimized Muscle Mass Loss In Trial

March 27, 2024 | investorplace.com

ALT Stock Earnings: Altimmune Beats EPS for Q4 2023

March 27, 2024 | msn.com

Altimmune GAAP EPS of -$0.54 misses by $0.16

March 27, 2024 | finance.yahoo.com

Altimmune Inc (ALT) Reports Q4 and Full Year 2023 Financial Results, Highlighting Pemvidutide's ...

March 27, 2024 | msn.com

Altimmune Obesity Drug Sheds Fat With Less Muscle Loss in Trial

March 27, 2024 | msn.com

Altimmune falls after Q4 results; obesity drug data released

See More Headlines

Receive ALT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Altimmune and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/08/2021
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ALT
CUSIP: N/A
CIK: 1326190
Web: altimmune.com
Phone: (240) 654-1450
Fax: 410-269-2601
Employees: 59
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $15.00
High Stock Price Target: $20.00
Low Stock Price Target: $12.00
Potential Upside/Downside: +117.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.65)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-88,450,000.00
Net Margins: -20,780.75%
Pretax Margin: -20,762.21%
Return on Equity: -44.77%
Return on Assets: -40.72%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 17.26
Quick Ratio: 17.26

Sales & Book Value

Annual Sales: $430,000.00
Price / Sales: 1,135.89
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.75 per share
Price / Book: 2.51

Miscellaneous

Outstanding Shares: 70,890,000
Free Float: 67,988,000
Market Cap: $488.43 million
Optionable: Optionable
Beta: 0.05

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Dr. Vipin K. Garg Ph.D. (Age 66)
President, CEO & Director
Comp: $986.14k
Dr. Matthew Scott Harris AGAF (Age 71)
FCAP, M.D., MS, Chief Medical Officer
Comp: $681.81k
Mr. Raymond M. Jordt M.B.A. (Age 51)
Chief Business Officer
Comp: $578.85k
Mr. Richard I. Eisenstadt M.B.A. (Age 66)
Chief Financial Officer
Comp: $619.69k
Mr. Bertrand Georges Ph.D.
Chief Technology Officer
Dr. M. Scot Roberts Ph.D. (Age 65)
Chief Scientific Officer
Comp: $599.25k
Mr. Tony Blandin B.S.
Vice President of Quality & Compliance Management
Mr. Andrew Shutterly M.S.
Corporate Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ALT Stock Analysis - Frequently Asked Questions

Should I buy or sell Altimmune stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Altimmune in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ALT shares.
View ALT analyst ratings or view top-rated stocks.
What is Altimmune's stock price target for 2024?: 3 Wall Street research analysts have issued 1-year target prices for Altimmune's shares. Their ALT share price targets range from $12.00 to $20.00. On average, they predict the company's share price to reach $15.00 in the next twelve months. This suggests a possible upside of 117.1% from the stock's current price.
View analysts price targets for ALT or view top-rated stocks among Wall Street analysts.
How have ALT shares performed in 2024?: Altimmune's stock was trading at $11.25 at the start of the year. Since then, ALT shares have decreased by 38.6% and is now trading at $6.91.
View the best growth stocks for 2024 here.
When is Altimmune's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ALT earnings forecast.
How were Altimmune's earnings last quarter?: Altimmune, Inc. (NASDAQ:ALT) announced its quarterly earnings data on Monday, November, 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by $0.45. The business earned $0.16 million during the quarter, compared to analyst estimates of $0.11 million. Altimmune had a negative trailing twelve-month return on equity of 44.77% and a negative net margin of 20,780.75%. During the same period in the previous year, the firm posted ($0.54) earnings per share.

When did Altimmune's stock split?: Altimmune's stock reverse split on the morning of Friday, September 14th 2018. The 1-30 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.
What other stocks do shareholders of Altimmune own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Altimmune investors own include Vaxart (VXRT), Pfizer (PFE), Verizon Communications (VZ), Amarin (AMRN), Advanced Micro Devices (AMD), Albireo Pharma (ALBO), Alliance Data Systems (ADS), AcelRx Pharmaceuticals (ACRX), Albertsons Companies (ACI) and Achieve Life Sciences (ACHV).
Who are Altimmune's major shareholders?: Altimmune's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include IMC Chicago LLC (0.00%) and EWG Elevate Inc. (0.01%). Insiders that own company stock include David Drutz, Diane Jorkasky, M Scot Roberts, Matthew Scott Harris, Vipin K Garg and Wayne Pisano.
View institutional ownership trends.
How do I buy shares of Altimmune?: Shares of ALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Altimmune (ALT) Stock Price, News & Analysis

Altimmune MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Altimmune Stock (NASDAQ:ALT)

ALT Stock Price History

ALT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ALT Stock Analysis - Frequently Asked Questions

Overall MarketRank^™